Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Petrie, J. R
Right arrow Articles by Kirby, M.
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Editorial

Too much of a good thing: 2004 guidance from NICE and BHS-IV on hypertension in diabetes

John R Petrie

Division of Medicine and Therapeutics, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK, johnp{at}memo.dundee.ac.uk

Mike Kirby

The Hertfordshire Primary Care Research Network The Nevells Road Surgery, Nevells Road, Letchworth, Herts, SG6 4TS, UK

References

  • He F., MacGregor G. Cost of poor blood pressure in the UK: 62,000 unnecessary deaths per year. J Hum Hypertens 2003;17:455-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Health Survey for England: Cardiovascular Disease. 1999. The Stationery Office London.
  • Morris AD Considerations in assessing effectiveness and costs of diabetes care: lessons from DARTS. Diabetes Metab Res Rev 2002;18 (suppl 3):S32-S35.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Investing in General Practice. The New General Medical Services Contract. BMA, February 2003 (see also www.dh.gov.uk/PolicyAndGuidance/OrganisationPolicy/PrimaryCare/PrimaryCareContracting/fs/en accessed 6th October 2004).
  • Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003;42:1206-52.[Abstract/Free Full Text]
  • Guidelines Committee. 2003 European Society for Hypertension- European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
  • Williams B., Poulter NR, Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society. J Hum Hypertens 2004;18:139-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • North of England Hypertension Guideline Development Group. Essential hypertension: managing adults in primary care. Centre for Health Services Research Report No 111, University of Newcastle on Tyne, 2004 (www.nice.org.uk/pdf/CG018fullguideline.pdf. Accessed 6th October 2004).
  • Law MR, Wald NJ, Morris JK, Jordan RE Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J 2003;326:1427-31.[Abstract/Free Full Text]
  • Ramsay LE, Williams B., Johnston GD et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 2003;13:569-92.[CrossRef]
  • Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,356 high risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Colhoun HM, Betteridge DJ, Durrington P. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Staessen JA, Wang J-G., Thijs L. Cardiovascular Prevention and blood pressure reduction a quantitative overview updated until 1 March 2003. J Hypertens 2003;21:1055-76.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Julius S., Kjelsen SE, Brunner H. et al. VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J S Hypertens 2003;16:544-8.[CrossRef]
  • Brown MJ, Cruickshank JK, Dominiczak AF et al. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003;17:81-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • McInnes GT `Size is not everything:' the Antihypertensive and LipidLowering treatment to prevent Heart Attack Trial (ALLHAT). Br J Diabetes Vasc Dis 2003;3:263-7.[Abstract/Free Full Text]
  • The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Svensson P., de Faire U., Sleight P. et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001;38:e28-e32.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Padwal R., Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 2004;27:247-55.[Abstract/Free Full Text]
  • UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998;317:713-20.[Abstract/Free Full Text]
  • Fretheim A. VALUE: analysis of results (letter). Lancet 2004;364:934-5.[Medline] [Order article via Infotrieve]
  • CS Lewis. That Hideous Strength (1945). London, Harper Collins (Paperback edition, 2000).

The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 6, 365-368 (2004)
DOI: 10.1177/14746514040040060101


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
British Journal of Diabetes & Vascular DiseaseHome page
M. Kirby
Has ASCOT signalled the end for beta blockers as first-line antihypertensive agents?
The British Journal of Diabetes & Vascular Disease, March 1, 2005; 5(2): 100 - 102.
[Abstract] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Petrie, J. R
Right arrow Articles by Kirby, M.
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?